Search
ASGCT 2026: Rgenta Therapeutics has been developing oral small molecules to regulate RNA - after starting with endogenous targets, they realized they could do the same for transgene expression
Co-Founder and CEO Simon Xi discusses the company's Rswitch platform, which was the basis of an ASGCT presentation showing that the company could modulate levels of Frataxin in a Friedreich’s Ataxia mouse model. Coverage brought to you by
May 13
.png){kind=logo}